Product Description

Anti-Human IL-33 Reference Antibody (Etokimab, RUO)

Sizes: 100ug, 1mg

Catalogue Numbers: HF543016-100, HF543016-1000

Lead times: 1-2 weeks, if manufacturer has product in stock

Manufacturer/Ship Location: China

Description: ANB020, now called etokimab, is currently in phase 2a testing in eczema, which is also known as atopic dermatitis. Scientists from the Medical Research Council Human Immunology Unit at the University of Oxford released data from 12 patients showing that 83% who were treated with etokimab reported a reduction in disease severity after 29 days. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. Etokimab is designed to block interleukin-33 (IL-33), an immune-signaling molecule. In peanut allergy, the body overreacts to peanuts as IL-33 activates an antibody called immunoglobin E. These antibodies cause allergic response such as mouth itchiness, hives, breathing difficulties and potentially fatal anaphylactic shock.

Reactivity: Human

Host: Humanized

Applications: ELISA, Bioactivity: FACS, Functional assay

Alternate Names: ANB020, 2022981-44-6, IL33

Clonality: Monoclonal

Isotype: IgG1-kappa

Target: NF-HEV, IL-1F11, C9orf26, IL-33, Interleukin-1 family member 11, IL33, Nuclear factor from high endothelial venules, NFHEV, Interleukin-33, IL1F11

Purification: Protein A/G purified from cell culture supernatant.

Purity: >95% as determined by SDS-PAGE.

Expression System: Mammalian Cells

Storage and Stability: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Storage Buffer: 0.01M PBS, pH 7.4.

Form: Liquid

Accession: O95760

Endotoxin Level: Contact Us for more information.

Research Use Only